FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organisation (CDMO) for biologics, viral vaccines and viral vectors, has confirmed a £400 million planned investment package at its UK facility in Billingham, Teesside. This investment package more than doubles the site’s existing development and manufacturing footprint, creating the largest multi-modal biopharmaceutical manufacturing site in the United Kingdom and is expected to create up to 350 highly-skilled jobs. The new facilities are expected to be operational by late 2023.
The new multi-modal campus will include two new state-of-the-art facilities (a viral gene therapy GMP facility and a GMP mammalian cell culture facility) and is part of a ¥90 Billion Yen global capital investment package initially outlined by FUJIFILM Corporation in June 2021.
Please visit here for the full press release.